48,989 Shares in Collegium Pharmaceutical, Inc. $COLL Acquired by NewEdge Wealth LLC

NewEdge Wealth LLC bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 48,989 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,773,000.

Several other institutional investors also recently bought and sold shares of the business. BlackRock Inc. purchased a new position in shares of Collegium Pharmaceutical during the 2nd quarter worth $196,972,000. Rubric Capital Management LP boosted its holdings in shares of Collegium Pharmaceutical by 5.3% during the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock worth $93,374,000 after purchasing an additional 157,743 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Collegium Pharmaceutical by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock valued at $104,465,000 after purchasing an additional 29,876 shares during the period. Janus Henderson Group PLC grew its position in shares of Collegium Pharmaceutical by 26.0% in the first quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company’s stock valued at $60,358,000 after purchasing an additional 377,073 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Collegium Pharmaceutical by 1.1% in the fourth quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock valued at $74,883,000 after purchasing an additional 18,160 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Barclays decreased their price target on Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a research note on Wednesday. Piper Sandler reiterated a “neutral” rating and set a $43.00 price objective (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday, August 7th. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Weiss Ratings cut shares of Collegium Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. Finally, Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.00.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock opened at $27.54 on Friday. The business’s fifty day moving average price is $33.82 and its 200 day moving average price is $35.84. Collegium Pharmaceutical, Inc. has a twelve month low of $25.47 and a twelve month high of $50.79. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. The stock has a market capitalization of $896.59 million, a P/E ratio of 22.21 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. The company had revenue of $199.88 million during the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The firm’s revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.68 earnings per share. As a group, research analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.51 earnings per share for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.